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Notch signaling pathway
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Abdul Samad Mumtaz, c Hussnain A. Janjua d and Nauman Khalid *e
Since the last decade, various genome sequencing projects have led to the accumulation of an enormous set of
genomic data; however, numerous protein-coding genes still need to be functionally characterized. These gene
products are called “hypothetical proteins”. The hypothetical protein pecanex-like protein 2 Homo sapiens
(PCNXL2) is found to be mutated in colorectal carcinoma with microsatellite instability; therefore, annotation
of the function of PCNXL2 in tumorigenesis is very important. In the present study, bioinformatics analysis of
PCNXL2 was performed at the molecular level to assess its role in the progression of cancer for designing
new anti-cancer drugs. The retrieved sequence of PCNXL2 was functionally and structurally characterized
through the web tools Pfam, Batch CD (conserved domain) search, ExPASy, COACH and I-TASSER directed
for pathway analysis and design to explore the intercellular interactions of PCNXL2 involved in cancer
development. The present study has shown that PCNXL2 encodes multi-pass transmembrane proteins whose
tumor suppressor function may involve regulating Notch signaling by transporting protons across the
membrane to provide suitable membrane potential for g secretase function, which may liberate the Notch
intracellular domain NICD from the receptor to inside the cell. Furthermore, domain A of PCNXL2 may exhibit
nuclear transport activity of NICD from the cytoplasm to the nucleus through interaction with a nuclear
localization signal that may act as an activator for Notch signaling in the nucleus. Conclusively, the tumor
suppressor role of PCNXL2 by regulation of the Notch signaling pathway and its functional and structural
characteristics are important ﬁndings. However, further studies are required to validate the putative role of
PCNXL2 as a cancer biomarker in cancer development.Introduction
Although the genome sequences of many organisms are avail-
able in databases, there are some proteins whose functions are
unknown; it is necessary to functionally characterize these
proteins, which are known as hypothetical proteins.1 The
sequences of these proteins are known, but no experimental
studies have been conducted to explore their functions. This is
due to the fact that the proteins are predicted using computa-
tional methods, which rely on signals in DNA sequences to
predict them as genes or based on their similarity to genes infe Sciences, University of Central Punjab,
dian@gmail.com; Tel: +92 301 5524624
istry, University of Gujrat, Gujrat 50700,
University, Islamabad 44500, Pakistan
y, Att-Ur-Rahman School of Applied
ces and Technology, H-12, Islamabad,
niversity of Management and Technology,
alid@umt.edu.pk; Fax: +92 42 3518478;
0other organisms. Therefore, it is very important to classify
hypothetical proteins in order to obtain new understanding of
regulatory and molecular processes in cells.
Functional annotations of hypothetical proteins and docking
sites provide an extensive outlook of essential biochemical path-
ways or the cellular processes responsible for the development and
prognosis of any disease in the body.2 The associations between
biologically relevant molecules such as proteins, nucleic acids,
carbohydrates, and lipids play central roles in signal transduction;
however, the relative orientation of the two interacting partners
may aﬀect the type of signal produced (e.g., agonism vs. antago-
nism).3 Therefore, docking is useful for predicting both the
strength and type of a signal produced by hypothetical protein–
ligand interactions to the appropriate target binding sites.4
Therefore, characterization of the binding behavior of hypothetical
proteins will play an important role in the rational design of drugs
with the elucidation of fundamental biochemical processes.
Pecanex homolog 2 (PCNXL2) is a protein-coding gene, and
homologs of this gene are present from Drosophila to humans.5
In Drosophila, it is observed that loss of pcx (pecanex) may cause
a neurogenic phenotype that may involve the N signaling
pathway. pcx resides in the endoplasmic reticulum inThis journal is © The Royal Society of Chemistry 2018
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View Article OnlineDrosophila, and its disruption causes enlargement of the ER;
this conrms its characteristic role in ER functioning.6 Previous
studies reported that frameshi mutations have been found in
FLJ11383 (PCNXL2) in patients suﬀering from colorectal carci-
noma.7 Although the incidence of mutations is high, the role of
these mutations in tumorigenesis is not yet clear. A study
demonstrated that PCNXL2 encodes a multipass trans-
membrane protein with unknown functions in Drosophila that
may be required during activation of the N signaling pathway.
Actually, pecanex (pcx) functionally encodes a multi-pass
transmembrane protein with unknown functions that is
widely found from Drosophila to humans; due to its maternal
neurogenic eﬀects, it may be involved in activation and regu-
lation of N signaling pathways.8 A study reported in Drosophila
described pcx as a component of the Notch signaling pathway
that is required upstream during activation of the pathway.6
Because pcx residues are present in the endoplasmic reticulum
and its disruption can cause ER enlargement, pcx may lead to
lateral inhibition of neuroblasts. No known predicted secondary
structures of PCNXL2 have been identied to date in humans.
Therefore, the detailed structure and function of this protein
must be determined to understand the signaling transduction
pathway. In humans, the Notch signaling pathway has diverse
consequences due to its cross-talk with other pathways or cell-
specic regulatory molecules; its disruption can lead to
pulmonary arterial hypertension, leukemia and several cancers
by inhibiting its tumor suppressor role in a cellular context.9
Notch signaling involves direct cell to cell communication
through interaction of the expressed ligand with the Notch
receptor of a neighboring cell. Ligand–receptor interaction
causes Notch activation by cleavage of the receptor through
activated g secretase to release the activated Notch intracellular
domain, NICD, in the cytoplasm; this is followed by trans-
location to the nucleus, where it may associate with the DNA
binding protein CSL and regulate the transcription of other
tumor suppressor genes.10 During cellular maturation, the
extracellular domain of N is cleaved by furin protease, ADAM10/
ADAM17 and g secretase to liberate the intracellular domain for
cell–cell Notch mediating signaling. N requires several post-
translational modications, such as O-glycosylation, for
optimal disulde bond formation in the extracellular domain
of N for activation of N signaling.11
pcx is a component of the N signaling pathway; however, the
exact molecular function of the pcx encoded multi-pass trans-
membrane protein is not known. The present study was con-
ducted to characterize PCNXL2 functionally and structurally to
understand its gene regulatory network; molecular docking was
performed to provide insight into its exact molecular process in
the N signaling pathway, which may be related to its tumor
suppressor role and its putative role as a cancer biomarker for
patient prognosis and therapeutic intervention.
Materials and methods
Sequence retrieval
The complete protein sequence of PCNXL2 was retrieved from the
NCBI Protein Database (https://www.ncbi.nlm.nih.gov/) andThis journal is © The Royal Society of Chemistry 2018GenBank (https://www.ncbi.nlm.nih.gov/genbank/) under the
specied accession number (NP_055616.3) and gene ID
(gi|134254443). A ow sheet of the methodology is provided in
Fig. 1.
Conserved domain prediction
Pfam, Batch CD and ScanProsite were used to predict the
conserved domains in PCNXL2 in order to characterize its
protein functions at the molecular level. Pfam (https://
pfam.xfam.org/) is a database containing a large collection of
protein families; each protein family is represented by multiple
sequence alignments (MSA) and hidden Markov models
(HMMs).12 The family of the hypothetical protein was identied
by searching consensus sequences in the structure coding
conserved domains of the PCNXL2 protein.13
A Batch CD search (https://www.ncbi.nlm.nih.gov/Structure/
bwrpsb/bwrpsb.cgi) was also performed to highlight conserved
domains in PCNXL2 for further conrmation of our results. This
program uses the NCBI web interface to explore the conserved
domain database within protein-coding sequences using
RPSBLAST, a variant of PSI-BLAST, and Position-Specic Scoring
Matrices (PSSMs).14 ScanProsite (https://prosite.expasy.org/
scanprosite/) allows searching of domains, functional sites and
protein families by comparing amino acid patterns in the
PCNXL2 protein.15 These predictions assisted in the character-
ization of the biochemical function of our hypothetical protein.
Prediction of physiochemical parameters
All proteins are dependent upon their structures and functions
and, in turn, upon their physical and chemical parameters in
a biological system. We used the ExPASy-ProtParam tool (https://
www.expasy.org/tools/protparam.html) and EMBOSSPepstats
(https://www.ebi.ac.uk/Tools/seqstats/emboss_pepstats/) to inves-
tigate the physical and chemical properties of PCNXL2 for its
functional validation in the lab.16 We submitted protein queries in
the form of a SWISS ID or protein sequence.17,18 The server directly
calculated the values of pI/MW (isoelectric point, molecular
weight), percentage of each amino acid, extinction coeﬃcient (EC),
instability index (II), aliphatic index (AI) and GRAVY (Grand
Average of Hydrophobicity) of the key protein query.19
Nature and cellular location of protein
We used the SOSUI server (https://harrier.nagahama-i-bio.ac.jp/
sosui/) to calculate the amphiphilicity index and hydropathy
index to estimate the nature of the PCNXL2 protein.20 The nature
of a protein indicates whether it resides in the cytoplasm or spans
the transmembrane. The SOSUI server contains an arsenal of tools,
such as SOSUI (Batch), SOSUIsignal, SOSUIgramN and SOSUImp1.
These tools were also utilized to predict part of the secondary
structure of PCNXL2 from its given amino acid sequence (AAS) to
estimate the location of the hypothetical protein in a cell.21
Protein–protein interaction network
A protein interacts with other proteins in the cell environment;
we studied these interactions in silico using STRING v9.1RSC Adv., 2018, 8, 21414–21430 | 21415
Fig. 1 Illustration of string analysis. The string analysis shows that PCNXL2 interacts with eight neighboring proteins as a result of biochemical
events and/or electrostatic forces. Literature analysis found only three proteins in the string network: actin-like 6 protein (ACTL6A), TATA box
binding associated factor RNA polymerase 1 B (TAF1B), and ﬁbulin-5 (FBLN5) play important roles in the regulation of cell fate, causing cancer by
interacting within the PCNXL2 signaling pathway.
RSC Advances Paper
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View Article Online(Search Tool for Retrieval of Interacting Genes). STRING
(https://string-db.org/) is a large repository of protein–protein
interaction networks, including functional interactions,21416 | RSC Adv., 2018, 8, 21414–21430regulatory interactions and stable complexes of proteins.22 We
searched the protein–protein interactions (PPIs) of PCNXL2 by
submitting a protein query sequence in the search box ofThis journal is © The Royal Society of Chemistry 2018
Paper RSC Advances
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View Article OnlineSTRING. STRING executes protein interactions by molecular
machines actively assembled by specic PPIs in the STRING
database.23 Determining the protein–protein interaction
network of PCNXL2 would empower our current study of
biochemical signaling pathways in cancer development.
Disulde bonding in the protein
Disulde bonds between cysteine residues of a protein play an
important role in the folding of the protein into a functional
and stable conformation. We used CYSPRED, DIANA and
CYSCON to predict disulde bonding within PCNXL2 to obtain
some insight into the experimental structure determination
and stability of the protein.
CYSPRED (https://gpcr.biocomp.unibo.it/cgi/predictors/
cyspred/pred_cyspredcgi.cgi) determines whether the cysteine
residues in your query protein form disulde bridges/bonds.
CYSPRED is a neural network-based predictor that is trained
to distinguish the bonding states of cysteine in proteins, start-
ing from the residue chain in its non-binding state, with high
eﬃciency.24
DIANA (https://clavius.bc.edu/clotelab/DiANNA/) was also
used because it helps predict the disulde connectivity of an
input protein sequence. Correct prediction of the disulde
bonds in a hypothetical protein is of crucial interest for
understanding the protein function and is key for tertiary
prediction methods.25 The tertiary structure of a hypothetical
protein will be helpful in identifying docking sites, moving one
step closer towards designing drugs that target diseases caused
by mutations in the PCNXL2 hypothetical gene.
One additional tool, CYSCON (https://www.csbio.sjtu.edu.cn/
bioinf/Cyscon/), was used for disulde bond prediction to
enhance and conrm the knowledge we obtained from the
abovementioned soware. CYSCON rst identied the most
condent disulde bonds within the hypothetical protein; then,
the prediction focused on the remaining cysteine residues based
on Support Vector Regression (SVR) training.26
Protein structure prediction
Protein structure prediction was performed to estimate the
location of all the atoms in the PCNXL2molecule using its amino
acid sequence through the computational methods RaptorX
(https://raptorx.uchicago.edu/) and Iterative Threading Assembly
Renement (I-TASSER) (https://zhanglab.ccmb.med.umich.edu/
I-TASSER/). First, RaptorX was used due to its excellent
secondary and tertiary structure predictions for longer hypo-
thetical protein molecules. The PCNXL2 protein sequence was
submitted to RaptorX to obtain the predicted 3D model, contact
map and solvent accessibility.27 The best model was selected on
the basis of P-value, GDT (global distance test), uGDT (un-
normalized GDT) and RMSD (root mean square deviation) by
estimating the absolute global quality and the absolute local
quality of each residue in the model.28 Second, I-TASSER was
used for detailed functional annotation of domains predicted in
our best model. I-TASSER cannot run longer protein sequences,
so we rst predicted domains in the complete 3D model of
PCNXL2 and then used I-TASSER to elucidate the biologicalThis journal is © The Royal Society of Chemistry 2018function of the protein. I-TASSER uses a hierarchical approach to
protein structure and function prediction.26 I-TASSER was used to
elucidate the biological functions of PCNXL2, including its gene
ontology, by comparing its structure and function prole with
those of known proteins; ligand binding site prediction, solvent
accessibility and enzyme commission number were determined
on the basis of a sequence-to-structure-to-function paradigm.29
Ligand binding site prediction
COACH (https://zhanglab.ccmb.med.umich.edu/COACH/) was
used for protein–ligand binding site prediction in PCNXL2.
COACH is a meta-server approach that uses two comparative
methods, TM-SITE and S-SITE, for ligand binding site predic-
tions. For the nal ligand binding site predictions, the TM-SITE
and S-SITE predictions were combined with COFACTOR
(https://zhanglab.ccmb.med.umich.edu/COFACTOR/), FindSite
(https://cssb.biology.gatech.edu/ndsite) and ConCavity
(https://compbio.cs.princeton.edu/concavity/).30 Domain
sequences of PCNXL2 were submitted in COACH, and 3D
models were constructed by I-TASSER. COACH outputs hot spot
sites on PCNXL2 for ligand binding aer ranking their physi-
cochemical properties, such as van der Waals potentials,
hydrophobicity, desolvation and electrostatic interactions.
miRNA target prediction
We further determined the potential role of PCNXL2 protein in
the treatment of cancer by ltering the PCNXL2 protein
sequence in miRTarBase. miRTarBase searched a list of
microRNAs targeting PCNXL2.31 miRTarBase (https://
mirtarbase.mbc.nctu.edu.tw/) is the experimentally validated
microRNA target interaction database.32 The miRNA-target
expression prole of the enlisted microRNAs was also studied
in miRTarBase to evaluate which microRNA expression is high
in a particular cancer based upon the Pearson coeﬃcient (r) and
probability value (P). A Pearson coeﬃcient ranging from 1 to
+1 indicates the type of correlation between the microRNA
expression level and the occurrence of cancer. 0 indicates no
relationship, while +1 indicates a strong positive correlation
and1 indicates a negative correlation. The probability value is
the criterion for the approval or rejection of a null hypothesis. If
the probability value is less than or equal to 0.005, our null
hypothesis of ‘‘high expression level of a particular microRNA
causes cancer by inhibiting PCNXL2 expression in a cell’’ is
rejected.
Pathway analysis and design
Finally, pathway analysis was performed by viewing gene
expression in the Cancer Genome Atlas and its involvement in
biological pathways of diﬀerent cancers.33 The Cancer Genome
Atlas (TCGA) was used in a comprehensive and coordinated
eﬀort to accelerate our understanding of the molecular basis of
cancer by visualizing the expression of the PCNXL2 gene in
a particular cancer. Reactome (https://www.reactome.org/),
a curated and peer-reviewed pathway database, was also used
for detailed study of the protein interactions playing important
roles in the transduction of a signaling pathway.34 LiteratureRSC Adv., 2018, 8, 21414–21430 | 21417
RSC Advances Paper
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View Article Onlineand KEGG pathways (https://www.genome.jp/kegg/
pathway.html) were also reviewed in order to generate
a hypothesis that these relevant molecular and regulatory
processes are controlled by selected microRNAs targeting
PCNXL2 in the progression of cancer.35 DAVID (https://
david.ncifcrf.gov/home.jsp) was also used to provide compre-
hensive information by using a set of computational tools to
evaluate the biological meaning of the list of genes interacting
with our hypothetical protein PCNXL2.36 We did not nd any
biological pathways related to PCNXL2 or any other related gene
pathways in the KEGG and Reactome databases. To address this
issue, we manually designed the pathway by reviewing the
literature to deepen our understanding of the function of
PCNXL2 in cancerous tissues.Results
PCNXL2 contains the pecanex_c conserved protein domain
family
Proteins are generally composed of one or more functional
regions, commonly named domains; characterization of these
domains is necessary to conrm the structure and functions of
a protein at the cellular level. The Pfam database suggests that
the hypothetical protein pecanex-like protein 2 Homo sapiens
(PCNXL2) contains the pecanex_c conserved protein domain
family (pfam05041) with the terminal region of the pecanex
protein homologs (pecanex protein C-terminus), as described in
Table 1. The pecanex protein is a maternal-eﬀect neurogenic
gene found in Drosophila. Searching with the Batch CD search
tool, a specic hit with a bit score of 384.928 and an E value of
9.69802  10122 indicates that clancl04904 (pecanex C super-
family) contains one domain and one cluster.
ScanProsite predicted that DNAJ_1 PS00636 (Nt-dnaJ domain
signature) belongs to the J protein family in PCNXL2, ranging
from 1270 to 1289 amino acids. DNAJ_1 regulates the activity of
hsp70, which is a molecular chaperone responsible for the
translocation of polypeptides across organelle membranes,
folding of nascent proteins, targeting proteins for degradation
and inferring responses to stress.37Table 1 Family distribution and physiochemical properties of PCNXL2 b
ProtParam tool EM
Sequence ID gi|134254443|r Ch
Family (Pfam) Pecanex_C superfamily Im
Domain (ScanProsite) DNAJ_1 Av
Alignment 1619–1844 A2
HMM length 229 A2
Bit score 369.2 Tin
E value 6.3  10111 Sm
Number of AA 2137 Ali
MW 237 276.9 Aro
pI 6.29 No
EC 246 635 Po
II 48.98 Ch
AI 87.45 Ba
GRAVY 0.204 Ac
21418 | RSC Adv., 2018, 8, 21414–21430PCNXL2 is a hydrophilic protein
The ProtParam tool computed various physiochemical proper-
ties of PCNXL2, such as its molecular weight, theoretical pI,
amino acid composition, atomic composition, extinction coef-
cient, estimated half-life, instability index, aliphatic index and
grand average of hydropathicity (GRAVY), as shown in Table 1.
The ProtParam tool calculated a pI of 6.9 and a MW of 237 276.9
for protein PCNXL2; these parameters assist in protein sepa-
ration through 2-D gel electrophoresis in the lab. The extinction
coeﬃcient (EC) shows the amount of light absorbed by a protein
relative to its amino acid composition at a specic wavelength
(280 nm); this enables estimation of the amount of pure protein
in a sample. The instability index (II) refers to the stability of
a protein in a test tube; for PCNXL2, the value is 48.98, which
classies the protein as unstable. The aliphatic index indicates
the relative volume of the aliphatic side chains. The aliphatic
index is regarded as a positive factor for increased thermosta-
bility of proteins. A higher AI value indicates increased ther-
mostatic stability of a protein. Sequence ID gi|134254443|r
PCNXL2 reects a moderate AI value of 87.45. The smaller the
grand average of hydropathy (GRAVY), the more hydrophilic the
protein. For PCNXL2, the GRAVY value is 0.204; this suggests
that PCNXL2 is a hydrophilic protein (Table 1). In the 3D
structure of a protein, hydrophilic domains tend to be found at
the exterior surface of the protein while hydrophobic domains
form the internal core of the protein.
EMBOSS Pepstats shows statistics of the physiochemical
properties of PCNXL2, such as the number andmolar percent of
each type of amino acid; by applying DayhoﬀStat, the number
and molar percent of each physiochemical class of amino acid,
the extinction coeﬃcient at 1 mg ml1 (A280) and the molar
extinction coeﬃcient (A280) can be obtained. The EMBOSS
Pepstats results showed that PCNXL2 exhibits 9.5 charges and
consists of up to 608 aliphatic, 238 aromatic, 1108 nonpolar and
1029 polar amino acids (Table 1). The aliphatic amino acids
compose the core of the protein, while polar and charged amino
acids are present on the surface of the protein and interact with
solvent molecules. The positive and negative amino acids form
salt bridges and maintain the three-dimensional structure ofy Pfam, EMBOSS Pepstats and ProtParam tool
BOSS Pepstats
arge 9.5
probability of expression in inclusion bodies 0.747
erage residue weight 111.033
80 extinction coeﬃcients 1 mg ml1 1.039
80 molar extinction coeﬃcients 246 635
y (A + C + G + S + T) 662
all (A + B + C + D + G + N + P + S + T + V) 1084
phatic (A + I + L + V) 608
matic (F + H + W + Y) 238
n-polar (A + C + F + G + I + L + M + P + V + W + Y) 1108
lar (D + E + H + K + N + Q + R + S + T + Z) 1029
arged (B + D + E + H + K + R + Z) 487
sic (H + K + R) 265
idic (B + D + E + Z) 222
This journal is © The Royal Society of Chemistry 2018
Paper RSC Advances
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View Article Onlinethe protein. The molar percentage of each amino acid reects
the ability of the protein to form secondary structures. The
amino acids M, A, L, E, K, G, Y, S, H, R, and Q prefer to adopt
helical conformations, while T, W, Y, F, I, and V prefer to adopt
b conformations. DayhoﬀStat predicted that most of the amino
acids in PCNXL2 (A, R, N, Q, E, K, H, P, S, T, W, and Y) have
negative scores; this characterizes PCNXL2 as hydrophilic.PCNXL2 is a multispanning membrane protein
The SOSUI server predicted that PCNXL2 is an endoplasmic
reticulum (ER) membrane protein consisting of 16 trans-
membrane helices (Table 2). Membrane proteins represent 50%
of the targets of all modern medicinal drugs; thus, PCNXL2 is
demonstrated to be a vital candidate for drug design against
cancers.
Other built-in soware in the SOSUI server, such as SOSUI
(Batch), conrmed that PCNXL2 is a 100% membrane protein.
SOSUIsignal predicted that PCNXL2 has no signal peptide, which
shows that PCNXL2 is not involved in the secretory pathways of
the cell. SOSUIgramN predicted that the inner membrane is the
subcellular localization site of PCNXL2. SOSUImp1 showed that
PCNXL2 is a multi-spanning membrane protein with potential to
perform functions such as signal transduction, immunological
reaction and cell adhesion (Table 3).PCNXL2 interacts with tumor suppressor proteins
STRING analysis showed that PCNXL2 experiences interactions
with neighboring proteins through various biochemical events
and/or electrostatic forces to perform various molecular
processes involved in homeostasis of the cell (Fig. 2). Aer
a through literature review, a comprehensive understanding of
the functioning of genes in cancer development was proposed.
The following proteins were observed in the string network: actin-
like 6 protein (ACTL6A), TATA box binding associated factor, RNA
polymerase 1 B (TAF1B), and bulin-5 (FBLN5); these play major
roles in the regulation of cell fate, suggesting that cancer in cells
involves their interactions with the PCNXL2 signaling pathway.Table 2 SOSUI results of PCNXL2
No. N-terminal Transmembrane region
1 63 TNSCHLYLWLFLLLLPLALHLAF
2 92 VFFYCSAVTIFFTIIKLVSYRLH
3 881 IVLVSLLGFLTLSQGFCKDMWVL
4 936 TYSRPIYFCVLCGLILLLDTGA
5 982 RDYLIVFLYCFPAISLLGLFPQI
6 1008 CTYLLEQIDMLFFGGSAVSGITS
7 1034 SVARSVLAAALLHAVCFSAVKEP
8 1059 MQHIPALFSAFCGLLVALSYHLS
9 1129 WDLIVCAVVAVLSFAVSASTVFL
10 1157 LSIVLFALAGAVGFVTHYVLPQL
11 1224 KYILYPALILNALTIDAFLISN
12 1249 LGTHWDIFLMIIAGMKLLRTSFC
13 1273 PVYQFINLSFTVIFFHFDYKDIS
14 1301 DFFMVSILFSKLGDLLHKLQFVL
15 1333 WGSSFHVFAQLFAIPHSAMLFFQ
16 1360 SIFSTPLSPFLGSVIFITSYVRP
This journal is © The Royal Society of Chemistry 2018Actin-like 6-A (ACTK6A) is a member of the SWI/SNF like
BRG1/brm associated factor (BAF) chromatin remodeling
complex that encodes BAF53a, the 53 kDa subunit of the BAF
complex in mammals.38 ACTL6A is involved in diverse cellular
processes, such as nuclear migration, chromatin remodeling
and transcriptional regulation. Recently, a study by Bao et al.39
demonstrated that SOX2 is a potential target of ACTL6A and
ACTL6A ectopic expression; enhanced SOX2 expression up-
regulates Notch 1 and triggers the Notch signaling pathway in
the cell. Hence, ACTL6A can enhance Notch activity in cells,
exhibiting a tumor suppressor function by targeting reduced
proliferation and apoptosis of cancerous cells. Another study by
Rowland and Peeper40 suggests that ACTL6A regulates the SWI/
SNF chromatin remodeling complex to suppress diﬀerentiation
in the epidermis by preventing SWI/SNF from binding to
promoters of KLF4 and other diﬀerentiation genes. KLF4 is
a transcription regulator that dictates diverse biological
processes, including pluripotency, cell diﬀerentiation, tumori-
genesis and proliferation.40
TATA box binding associated factor RNA polymerase 1 B
(TAF1B) is a component of the RNA polymerase 1 core factor
complex; it plays active roles in multiple steps during tran-
scription initiation, such as pre-initiation complex (PIC)
assembly and post polymerase recruitment events. TAF1B, the
second largest component of TATA-binding protein (TBP),
binds to ribosomal DNA by recruiting POL1 to the SL1/TIF-IB
complex through its interaction with RRN3.41 A study demon-
strated that MARCK2, PCNXL2 and TAF1B are putative target
genes in colorectal carcinoma with microsatellite instability.7
PCNXL2 (74%) and TAF1B (82%) were found to be mutated in
MSI-H colorectal carcinomas. This study reported that frame-
shi mutations of the three abovementioned target genes are
related to functional inactivation by generating truncated
proteins and may be related to tumorigenesis. Cell cycling and
protein synthesis are key regulatory tasks for cancerous cells.
TAF1B is involved in the synthesis of proteins and mutations
and has been found in many cancers; therefore, we can
conclude that mutations result in truncated proteins which areC-terminal Type Length
85 PRIMARY 23
114 PRIMARY 23
903 PRIMARY 23
957 PRIMARY 22
1004 PRIMARY 23
1030 SECONDARY 23
1056 PRIMARY 23
1081 SECONDARY 23
1151 PRIMARY 23
1179 PRIMARY 23
1245 PRIMARY 22
1271 SECONDARY 23
1295 SECONDARY 23
1323 SECONDARY 23
1355 SECONDARY 23
1382 SECONDARY 23
RSC Adv., 2018, 8, 21414–21430 | 21419
Table 3 Comparison of SOSUI (Batch), SOSUIsignal, SOSUIgramN and SOSUImp1 results
SOSUI (Batch) SOSUI signal SOSUIgramN SOSUImp1
Nature Percentage Signal peptide Nature Subcellular localization site Spanning membrane protein
Membrane protein 100% No Soluble IM (inner membrane) Multi
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View Article Onlineunable to perform their functional roles in the homeostasis of
cells. Furthermore, these mutations may inactivate tumor
suppressor genes and DNA repairing genes in cells by providing
a suitable cancerous microenvironment which initiates
tumorigenesis.
Fibulin-5 (FBLN5) is a member of the bulin family that is
widely expressed as an extracellular matrix protein (ECM) and is
involved in cell-to-matrix or cell-to-cell communication, elasto-
genesis, cell adhesion and cell mobility.42 Fibulin-5 is a 66 kDa
glycoprotein that is localized in elastic ber and is involved in
regulating elastic ber assembly. It has a unique RGD domain
which can bind to integrins on cell surface receptors. Integrins
regulate intracellular signaling through extracellular signal-
regulated kinase (ERK), and focal adhesion kinase (FAK)
mediates cell adhesion to the extracellular matrix.43 The Notch
signaling pathway performs its tumor suppressor role by
inhibiting Wnt/b catenin signaling through increased p21
expression, which may act as a negative modulator of Wnt-4.
Fubilin-5 also acts as a metastasis suppressor by inhibiting
the Wnt/b catenin pathway through inhibition of ERK via its
unique RGD domain, leading to activation of GSK3b. GSK3b
downregulates b-catenin by proteasomal degradation, prevent-
ing its translocation to the nucleus; this leads to suppression of
the oncoproteins metalloproteinase-7 (MMP-7) and c-Myc.44Fig. 2 Predicted model for the whole sequence of PCNXL2. (RaptorX re
21420 | RSC Adv., 2018, 8, 21414–21430PCNXL2 is a cysteine-rich protein
CYSPRED predicted that cysteines which are capable of forming
disulde bonds within PCNXL2 are responsible for the stability
of the protein (Table 4). When more disuldes are present in
a protein, the protein will be more stable, with a positive signal
for the 3-D structure of the hypothetical protein. DIANA pre-
dicted that the disulde bond topology in PCNXL2 is of crucial
importance for understanding its function and its tertiary
prediction methods. DIANA showed the bonds that are pre-
dicted to be present between respective cysteine residues within
PCNXL2, which represents a further step towards the design of
anti-cancer drugs by targeting hypothetical protein molecular
docking sites (Table 4).
CYSCON, a disulde bond predicting soware program,
predicted SSBonds for the cysteine residues of PCNXL2 (Table
4). These results display a new path to improve the ab initio
structure modeling of cysteine-rich proteins such as PCNXL2.PCNXL2 structure and function
A web-based tool, RaptorX, generated the best domain of our
PCNXL2 protein sequence and predicted the secondary and
tertiary structures for the complete sequence of PCNXL2 (Fig. 3).
RaptorX modulated two domain structures solely by taking thesults: current status of the model of PCNXL2 is complete).
This journal is © The Royal Society of Chemistry 2018
Table 4 Prediction of cysteine residues involved in disulphide bonding by CYSPRED, DIANA and CYSCON
CYSPRED DIANA CYSCON
Cysteine Prediction Reliability Sequence ID Bonded cysteine SSBOND
Cysteine
residues
CYS 144 Bonding state 8 gi|134254443|r 34–1239, 64–337, 144–1402, 290–880,
312–614, 315–874, 331–797, 445–467,
519–1634, 652–715, 736–1472, 865–1473,
912–1587, 915–2086, 959–1418, 976–
1475, 1017–1038, 1064–1781, 1102–2101,
1189–1873, 1454–2114, 1474–1924, 1486–
1821, 1597–1704, 1607–1728
SSBOND#1 34–2114
CYS 290 Bonding state 1 SSBOND#2 64–2086
CYS 312 Bonding state 2 SSBOND#3 144–2101
CYS 315 Bonding state 8 SSBOND#4 290–1924
CYS 331 Bonding state 8 SSBOND#5 312–1821
CYS 337 Bonding state 2 SSBOND#6 315–1873
CYS 467 Bonding state 8 SSBOND#7 331–1781
CYS 519 Bonding state 1 SSBOND#8 337–1728
CYS 715 Bonding state 1 SSBOND#9 445–1704
CYS 736 Bonding state 1 SSBOND#10 467–1634
CYS 1418 Bonding state 8 SSBOND#11 614–652
CYS 1472 Bonding state 8 SSBOND#12 715–736
CYS 1473 Bonding state 8 SSBOND#13 1017–1038
CYS 1474 Bonding state 4 SSBOND#14 1402–1418
CYS 1475 Bonding state 4 SSBOND#15 1587–1597
CYS 1607 Bonding state 4
CYS 2086 Bonding state 2
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View Article OnlineFASTA format of the PCNXL2 protein. The soware results for
PCNXCL2 comprise three sections which contain important
information about its secondary structure modeling. The
quality of the predicted model depends on three critical
parameters: P-value, Score and uGDT (GDT). The results were
divided into three section boxes; Section 1 contains the input
protein sequence and domain prediction, Section 2 containsFig. 3 Predicted structure of the selected domain.
This journal is © The Royal Society of Chemistry 2018a summary of the predicted results in detail along with the most
promising predicted complete structure of PCNXL2, and
Section 3 is the main hotspot section of our study because it
contains structural and functional annotations of crucial pre-
dicted domains. These sections were examined in sequence: the
1st section divides the whole sequence of the protein into its
residues, and each of the amino acids exhibits a domainRSC Adv., 2018, 8, 21414–21430 | 21421
Table 5 Structure prediction and functional annotation by RaptorX
Summary of predicted model
Domains 2
Best template 3m1iC
Probability value ‘P-value’ 7.8  107
Overall uGDT 136
GDT 6
Modeled residue count 1144
Disordered position count 913
Secondary structure details 31% H (helix), 8% E (beta sheet),
60% C (loop)
RSC Advances Paper
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View Article Onlineassignment; each residue is given a particular number, and the
residues marked by ‘0’ are not part of the modeling process due
to the absence of matches in the PDB templates. The total no. of
residues that were generated by the soware for PCNXL2 is
2131.
The second section contains information about the domain
number. The best template is 3m1iC; it has a probability P-value
of 7.8 107, which is less than the threshold and is considered
to be a good model. The current model comprises 2131 residues
with uGDT (136) and GDT (6), further conrming the viability of
the model (Table 5).
The most important and targeted section of our study is the
3rd section, ‘detailed prediction results’, which contains rele-
vant functional and structural information about the two pre-
dicted domains. The best model was selected on the basis of P-
value using the templates 3m1iC, 3gjxA, 4gmxC, 4fgvA, and
4c0oA for the rst domain and 4he8: I for the second domain;Fig. 4 Illustration of the best predictedmodel for domain A. Because the
models, with an estimated TM score of 0.57  0.15 and an RSMD of 11.9
21422 | RSC Adv., 2018, 8, 21414–21430all the templates have diﬀerent functions in the cell. To select
the best-predicted domain, various parameters were used, such
as rank, P-value, uGDT (GDT), uSeqId (SeqId), and Score. The
rst domain (domain A) has rank: 0, P-value: 7.8  107, uGDT
(GDT): 98 (9), uSeqId (SeqId): 93 (9), and Score: 237; it contains
1054 amino acids, with a sequence from 821 to 1875. In
contrast, the second domain has rank: 1, P-value: 4.55  103,
uGDT (GDT): 38 (43), uSeqId (SeqId): 10 (11), and Score: 53; it
contains 89 amino acids, from 1 to 89. All values for the rst
domain A are close to the threshold, with P-values less than
0.005; the uGDT must be greater than 50 and the Score must be
in the range of 0 to the domain sequence length. This domain
was considered to be the best domain compared to a second
domain, whose values varied considerably from this threshold
value (Fig. 4).
I-TASSER was applied to obtain comprehensive structural
and functional understanding of the RaptorX-predicted
domain. Domain A consists up of 1054 amino acids, from
amino acids 821 to 1875 in the PCNXL2 protein. Pfam revealed
the presence of a pcx domain from amino acids 1619 to 1844 in
PCNXL2; thus, the pcx domain can be considered to be part of
domain A. Therefore, the sequences of domain A and pcx were
submitted separately in I-TASSER for structure and function
predictions.
The secondary structure of domain A showed that it is
enriched with long stretches of a helixes (M, A, L, E, K, G, Y, S,
H, R, Q) and loops with a condence score of 9, followed by
a few short stretches of b sheets (T, W, Y, F, I, V), suggesting that
the core region in domain A is an a helix secondary structure
element. The remaining amino acids (P, G, S, D, and N) disruptC score of model 1 is higher (1.18) than those of the other 4 predicted
 4.4 A˚, it is considered to be the best predicted model for domain A.
This journal is © The Royal Society of Chemistry 2018
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View Article Onlinethe secondary structure and give rise to loops or turns called
secondary structure breakers. The remaining amino acids (P, G,
S, D, and N) disrupt the secondary structure and give rise to
loops or turns called secondary structure breakers. Prediction of
the solvent accessibility discovered buried and exposed regions
of domain A with values ranging from 0 (buried residue) to 9
(exposed residue). Most of the residues in the domain have
0 values, showing their involvement in the core region of the
protein; residues with higher values are hydrophilic and can
potentially be involved in hydration processes. The predicted
normalized B factor estimates the thermal mobility of residues
in a protein. The residues at the N and C termini have positive
normalized B factors, indicating that these regions are relatively
stable; meanwhile, the a and b regions have values that are
either negative or close to 0, revealing that these regions are
structurally stable. The arrangements of particular amino acids
in a primary structure determine the secondary and tertiary
globular structures of a protein by sequestration of hydrophobic
amino acids in the core and enrichment of hydrophilic amino
acids on the surface. The top ve models were generated by I-
TASSER. The model with the highest condence score (C
score; 1.18), TM score (0.57  0.15) and RMSD (11.9  4.4 A˚)
was considered to be the best-predicted model for domain A
(Fig. 5). Aer selection, the best-predicted model was aligned
against all known protein structures in the PDB database to nd
proteins that are structurally close to our target protein. TenFig. 5 Illustration of the best predicted model for the pcx domain.
Because the C score of model 1 is higher (4.20) than those of the
other 4 predicted models, with an estimated TM score of 0.27  0.08
and an RSMD of 15.9  3.2 A˚, it is considered to be the best predicted
model for the pcx domain.
This journal is © The Royal Society of Chemistry 2018protein structures close to the target were predicted. One PDB
structure (3w3tA) with a C score close to 0.9 was observed and
was selected for further functional study of the target protein.
The model (2vdcA) with the highest EC score (0.122) and TM
score (0.338) was selected; it was found to be a glutamate syn-
thase with an EC number of 1.4.1.13. Finally, gene ontology
(GO) was performed to determine the function of domain A.
This section comprises two parts; the rst shows 10 homolo-
gous GO templates, while the second is a consensus prediction
of GO terms, including molecular function, biological process,
and cellular components. A true positive template was selected
by analyzing the functional homology score (Fh score) between
the target and template proteins and by estimating the con-
dence level. The rst two templates, 1qgkA and 2z5kA, were
selected with Fh scores of 0.08 and C scores of 0.09 and 0.08,
respectively. The GO term predicted that the cellular compo-
nent of domain A is the cytosol. A literature review of these
proteins revealed that domain A exhibits nuclear transport
activity; thus, it may transport macromolecules or substrates
from the cytoplasm to the nucleus by interacting with nuclear
localization signals.45 This domain may also play roles in bio-
logical processes by phosphodiester bond hydrolysis.46
The secondary structure of the pcx domain showed that it is
enriched with long stretches of a helixes (M, A, L, E, K, G, Y, S,
H, R, Q) with a condence score of 9, followed by a very small
number of short stretches of b sheets (T, W, Y, F, I, V), sug-
gesting that the core region in the pcx domain is an a helix
secondary structure element. Most of the residues in the pcx
domain have scores of 9, showing that they are hydrophilic and
may undergo hydration or act as active sites. In the pcx domain,
the residues at the N and C termini were predicted with positive
normalized B factors, indicating that these regions are relatively
stable; meanwhile, the values in the a and b regions are either
negative or close to 0, revealing that these regions are struc-
turally more stable. The best-predicted model by I-TASSER for
the pcx domain has a higher C score (4.20), TM score (0.27 
0.08) and RMSD (15.9  3.2 A˚) (Fig. 6). Aer selection, the best-
predicted model was aligned against all known protein struc-
tures in the PDB database, and ten protein structures close to
the target were predicted. Three closer protein structures,
5cwcA, 5cwoA and 2zxeA, with TM scores greater than 5 were
selected for further functional study of our target protein. The
enzyme commission number and active site predicted 5 models
for the target protein. The model (imhsA) was selected with the
highest EC score of 0.065 and TM score of 0.503, illustrating
that it is a proton transport ATPase with an EC number of
3.6.3.6. Gene ontology (GO) demonstrated the molecular func-
tion of the pcx domain using 10 homologous GO templates.
True positive templates, 3ixzA and 2zxeA, were selected by
analyzing their Fh scores (0.07 and 0.06, respectively). The GO
term predicted that the cellular component of the pcx domain is
an intrinsic component of the cell membrane which spans or
embeds both leaets around the membrane. A literature review
of these proteins revealed that the pcx domain exhibits ATPase
activity coupled to transmembrane movement of ions (protons)
by establishing membrane potential for essential biological
processes, such as the liberation of an activated protein fromRSC Adv., 2018, 8, 21414–21430 | 21423
Fig. 6 Illustration of the ligand binding site predictions of domain A.
The ligand binding site predictions of domain A were executed by
COACH, combining the results from ﬁve algorithms: COFACTOR, TM-
SITE, S-SITE, FindSite and ConCavity. The ﬁrst PDB hit, 3y3yA, was
selected with a C score of 0.06, a cluster size of 4 and binding to the
peptide ligand. The predicted ligand binding is indicated with yellow-
green spheres, and the corresponding binding residues are shownwith
blue balls and sticks.
RSC Advances Paper
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View Article Onlinereceptors. A domain can play roles in biological processes by
performing particular functions in the cell.PCNXL2 ligand binding interactions
The PDB le of the best predicted domain-A model was
submitted to COACH for ligand binding site predictions by
matching target models in the BioLip database. 10 models were
predicted by COACHwith diﬀerent ligands. Selection of amodel
was conducted on the basis of C score; the higher the C score,
the more reliable the model. The rst PDB hit, 3y3yA, was
selected with a C score of 0.06 and a cluster size of 4. This model
binds to the peptide ligand. In addition to the peptide ligand, it
can bind with other ligands available in the “mult” link. COACH
also combines the results of ve algorithms, including
COFACTOR, TM-SITE, S-SITE, FindSite and ConCavity, as
illustrated in Fig. 7.21424 | RSC Adv., 2018, 8, 21414–21430COACH also predicted 10 models for ligand binding inter-
actions of the pcx domain. The best model was considered to be
3fu1A, with a C score of 0.05 and a cluster size of 3; it binds to
the zinc (Zn) ligand. The RAP ligand model can also bind with
other ligands available in the “mult” link. The combined results
of ve algorithms, including COFACTOR, TM-SITE, S-SITE,
FindSite and ConCavity, are illustrated in Fig. 8.
miRNAs down-regulating expression of PCNXL2
miRTarBase, the experimentally validated microRNA-target
interactions database, predicted microRNAs targeting PCNXL2
with their expression proles in various cancers, such as pros-
tate cancer.47,48 MicroRNAs with r values close to 1 have a linear
relationship between their expression and cancer incidence.
MicroRNAs with P values greater than 0.005 accept the null
hypothesis that states that a higher level of expression of
microRNAs targeting PCNXL2 is the cause of cancer in humans.
Aer searching with miRTarBase, 58 microRNAs were found in
humans targeting PCNXL2, which were further shortlisted on
the basis of the hypothesis.
The miRNA-target expression proles of the enlisted micro-
RNAs were also studied in miRTarBase to evaluate which
microRNA expression is high in a particular cancer based upon
the Pearson coeﬃcient (r) and probability value (P).49 In this
expression prole, miRNA was checked against the PCNXL2
mRNA level in a particular cell by viewing and studying graph-
ical charts. miRNAs which have positive R values in particular
cancers are considered to have a positive linear relationship,
justifying that targeted PCNXL2 expression is directly propor-
tional to miRNA expression for a particular cell. Meanwhile,
miRNAs which have negative R values are considered to have
a negative linear relationship, justifying that targeted PCNXL2
expression is down-regulated with increased expression of the
miRNA in a particular cancer. To accept the null hypothesis, the
miRNA must have a P-value greater than 0.005, justifying that
a high expression level of a particular microRNA causes cancer
by inhibiting PCNXL2 expression in a particular cell type. The
expression of selected miRNAs has been experimentally vali-
dated to have a negative linear relationship with PCNXL2 mRNA
in diﬀerent cancers and cells, as shown in Table 6.
PCNXL2 regulates the Notch signaling pathway
The hypothetical protein pecanex-like protein 2 Homo sapiens
(PCNXL2) is an endoplasmic membrane protein consisting of
up to 16 transmembrane helixes and containing a pecanex_c
conserved protein domain. PCNXL2 is mostly present in the ER
and contributes to some biological processes that occur in the
ER. In a previous study, Yamakawa et al.8 described that peca-
nex (pcx) encodes a multipass transmembrane protein with
unknown functions that may be involved in the N signaling
pathway. In this study, we hypothesize that pcx has functions in
the Notch signaling pathway and cancer.
Proper folding of Notch (N) protein is essential for its acti-
vation; therefore, the formation of disulde bonds in the
extracellular domain of N is required for its proper folding by
Ero1L. When an unfolded and misfolded protein appears in theThis journal is © The Royal Society of Chemistry 2018
Fig. 7 Illustration of the ligand binding site predictions for the pcx domain. The ligand binding site predictions of the pcx domain were executed
by COACH, combining the results from ﬁve algorithms: COFACTOR, TM-SITE, S-SITE, FindSite and ConCavity. The bestmodel was considered to
be 3f1uA due to its higher C score (0.05) and cluster size of 3; also, it binds to the Zn ligand. The predicted ligand binding is indicated with yellow-
green spheres, and the corresponding binding residues are shown with blue balls and sticks.
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View Article OnlineER, the organelle suﬀers stress known as “ER stress”. This stress
can induce apoptosis. The cell can reduce its stress level
through a response known as unfolded protein response (UPR),
described by Yamakawa et al.8 The unfolded protein response
(UPR) is a response that enables the body to cope with ER stress.
In stressed cells, Ire-1 is an ER tethered endonuclease that acts
as a sensor of ER stress and splices Xbp1 mRNA, which
promotes protein folding and results in the transcriptional
induction of genes such as Ero1L.50 ER-associated degradation
(ERAD), aggresome formation and autophagic processes are
also coping responses of the body to ER stress.
Therefore, the disruption of the N-signaling pathway in the
absence of pcx function may be partially due to misfolding of N
because pcx acts upstream of the activated form of N and
probably functions in signal receiving in cells by providing
stability to the N protein to aid its proper functioning. The
structure of pcx suggests that it plays a role in the formation of
disulde bridges in the extracellular domain of N by providing
cohesion and stability for its proper folding by enabling its
expression in the cell. Pecanex-like protein 2 Homo sapiens
(PCNXL2) releases a multi-pass transmembrane protein with
1054 amino acids comprised of domain A and the pcx domain
from the inner membrane of the ER into the cytosol. Because
PCNXL2 also contains a DNA_J domain, it facilitates the
translocation of polypeptides across organelle membranes.51
Domain A is found to be present in the cytosol, while the pcxThis journal is © The Royal Society of Chemistry 2018domain is an intrinsic component of the cell membrane. Notch
signaling is activated by binding Notch ligands to Notch
receptors on signal-receiving cells, which leads to activation of g
secretase for cleavage of the receptor to release and translocate
the Notch intracellular domain NICD to the nucleus. For proper
function of g secretase, the active site must contain water to
carry out hydrolysis in the hydrophobic environment of the
membrane; however, it is not understood how water and proton
exchange are eﬀected. Here, we demonstrate that the pcx
domain may exhibit ATPase activity coupled to transmembrane
movement of ions (protons) by establishing membrane poten-
tial for essential biological processes such as the liberation of an
activated protein (NICD) from receptors. The pcx domain may
play its role by establishing localization of the activated domain
in a cell. Furthermore, domain A exhibits nuclear transport
activity of macromolecules or substrates (NICD) from the cyto-
plasm to the nucleus by interacting with a nuclear localization
signal (Fig. 9). Domain A may also play a role in biological
processes by phosphodiester bond hydrolysis. In the nucleus,
NICD binds to transcriptional factor CSL to activate the
expression of Notch signaling.52
There are diverse consequences of the Notch signaling
pathway; among these, cyclin/CDK inhibitor p21WAF1/CLIP1 is an
important target of Notch signaling. Increased Notch 1 activity
leads to increased p21 expression, a key modulator of negative
regulation of Wnt-4 expression of the Wnt/b catenin signalingRSC Adv., 2018, 8, 21414–21430 | 21425
Fig. 8 Illustration of PCNXL2 regulating the Notch signaling pathway. PCNXL2 present in the ERmembrane releases a protein consisting of up of
1054 amino acids containing domain A and the pcx domain. The pcx domain exhibits ATPase activity coupled to transmembrane movement of
ions (protons) by establishing a membrane potential for essential biological processes, such as liberation of the activated protein NICD from
receptors. Domain A exhibits nuclear transport activity; it transports NICD from the cytoplasm to the nucleus to transcriptional factor CSL to
activate the expression of Notch targeted tumor suppressor genes and to downregulate tumor oncogenes, including p21, p53, p27, Smad, p63,
p65, as well as WNT signaling and AP1\HPV\MRCKa.
RSC Advances Paper
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinepathway.53 The crosstalk between the p21WAF1/CLIP1, Notch and
the Wnt/b catenin pathway is important for regulation of tumor
development by preventing the proliferation of tumor cells
through down-regulating the Wnt signaling pathway and
expression of its oncogenes.54 Another target of Notch activation
is induction of the NF-kB pathway, promoting cytokine
production for the development of innate and adaptive immu-
nity in cells for growth control and apoptosis.55 A negative
feedback loop is present between Notch and p63, and p63
overexpression has been found in many cancers; p63 expression
is suppressed by the activation of Notch through selective
modulation of interferon-responsive genes. Like p63, the small
GTPases Rho, Rac and CD42 have inverse relationships with
Notch activation in the control of stem cell potential and tumor
development.56 Notch CBF-dependent mechanisms achieve
tumor suppression by downregulating ROCK1/2 and MRCKa
kinases, which are key regulators of overexpressed Rho GTPase
in tumors. Another consequence of Notch activation is the
down-regulation of HPV oncogene expression; Notch 1 is under
the direct eﬀect of p53, so increased levels of p53 upregulate the
expression of Notch in respective cells either through the inhi-
bition of endogenous AP-1 activity or through other indirect
mechanisms.57 P53 and its relatives are also key regulators of
noxa expression; the P53 status of a cell regulates noxa expres-
sion. Noxa activation is followed by its interaction with Bcl-2
family members, freeing Bax/Bak and promoting apoptosis to21426 | RSC Adv., 2018, 8, 21414–21430mitochondria through caspase cascade activation.58 An addi-
tional target of Notch activation is the suppression of FoxO3a,
which is a key transcriptional factor responsible for deciding
the fate of a cell either by promoting tumor metastasis or
increased cancer cell invasion. The canonical Notch/HERP
pathway is a promising negative regulator of FoxO3a by
binding of the HSE/HRE/Tle transcription repressor complex to
the promoter of FoxO3a.59 Cross-talk between the Notch and
transforming growth factor-b (TGF-b) signaling pathways plays
critical roles in the control of cell fate by regulating Hes-1
expression, an important target of the Notch pathway. NICD
and Smad3 interact directly in a ligand-dependent manner;
Smad3 can be recruited to CSL-binding sites on DNA in the
presence of CSL and NICD, indicating that Notch and TGF-
b signaling are integrated through direct protein–protein
interactions.60
We conclude that the pecanex protein is a tumor suppressor
protein regulating Notch signaling to perform its tumor-
suppressing function in developing cells, preventing misfold-
ing of N proteins that can cause proliferation, cell survival,
tumor invasion and expression of oncogenes.Discussion
Pecanex-like protein 2 Homo sapiens (PCNXL2) is a member of
the evolutionarily conserved pecanex_c conserved proteinThis journal is © The Royal Society of Chemistry 2018
Table 6 Expression proﬁle of microRNAs targeting PCNXL2 in various cancers
MicroRNA
Colorectal
carcinoma
Breast
cancer
Pancreatic
cancer
Prostate
cancer
CNS germ
cell tumor
Multiple
myeloma
Diﬀerentiated embryonic
stem cell tumor
hsa-miR-154-5p 3 3 3 - 3 3 3
hsa-miR-382-5p 3 3 - 3 3 - 3
hsa-miR-335-3p 3 - - 3 - - -
hsa-miR-548d-3p 3 3 - - 3 - -
hsa-miR-512-3p 3 3 3 3 3 3 -
hsa-miR-520e 3 3 3 - 3 3 -
hsa-miR-520d-3p 3 - - 3 3 3 -
hsa-miR-520c-3p 3 3 - - - 3 -
hsa-miR-520b 3 3 3 - - - -
hsa-miR-520a-3p - 3 - - - - -
hsa-miR-373-3p 3 3 3 - - 3 -
hsa-miR-302c-3p - 3 3 - - 3 -
hsa-miR-302b-3p - 3 - - - 3 -
hsa-miR-302a-3p 3 3 3 - - 3 -
hsa-miR-93-5p 3 3 - - 3 3 -
hsa-miR-20b-5p 3 3 3 - 3 - -
hsa-miR-20a-5p - 3 3 - - - -
hsa-miR-17-5p 3 - - - - - -
hsa-miR-106b-5p 3 3 - - - - -
hsa-miR-106a-5p - - - - 3 - -
hsa-miR-1283 - 3 3 - 3 3 -
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View Article Onlinedomain family. The pecanex_c conserved protein domain
family comprises multi-pass transmembrane domains of large
transmembrane proteins.8 In previous literature studies, pcx
was suggested to be part of the N signaling pathway, with its
mutant in Drosophila based upon its neurogenic phenotype.61
Recently, a study published by Yamakawa et al.8 demonstrated
that pcx is a component of the N signaling pathway in
Drosophila by encoding a multi-pass transmembrane protein of
unknown function; the possible functions of this protein have
not yet been explored. In this study, we have provided evidence
that PCNXL2 encodes a multi-pass transmembrane protein that
regulates the Notch signaling pathway in humans as a cancer
biomarker.
Previously, frame shi mutations were found in FLJ11383
(PCNXL2) in patients suﬀering from colorectal carcinoma.
Although the incidence of mutations was high, the role of these
mutations in tumorigenesis was not clear.7 The current study
suggests that pcx is independently involved in activation of the
Notch signaling pathway by transporting protons across the
membrane, thus establishing a membrane potential gradient to
release embedded water to the active site of g secretase chan-
neling; this provides a suitable environment for hydrolysis to
proceed, with liberation of NICD from the receptors. Therefore,
it was not previously understood how water and proton
exchange were eﬀected to carry out hydrolysis in the hydro-
phobic environment of the membrane, which is the focus of the
current research.62 Furthermore, domain A induced interaction
with nuclear localization to transport NICD in the nucleus for
the activation of tumor repressor genes in signal receiving cells.
However, the results suggest that the downregulation of
PCNXL2 in signal receiving cells may inhibit the proper func-
tion of g secretase. It may also partially cause truncated N
protein synthesis with deregulation of the Notch signalingThis journal is © The Royal Society of Chemistry 2018pathway, resulting in cancer development; this is consistent
with our hypothesis that pcx regulates the N signaling pathway
by providing a suitable membrane environment for the genesis
of activated N protein in signal-receiving cells.
Other possible reasons include the induction of several
downstream events by the activated N protein synthesis,
including regulation of the Notch signaling pathway, over-
expression of tumor suppressor genes and inhibition of Wnt
signaling. Therefore, Notch signaling cross-talk with other
pathways may enhance the complex sub branched mechanism
of PCNXL2, with compensated up-regulation of Notch targeted
tumor suppressor genes p21, p53, and p27; this can lead to
down-regulation of oncogenes, proliferation, diﬀerentiation,
and cell cycle and growth arrest.63
Previous literature studies also conrmed that improper or
misfolded PCNXL2 protein-induced ER stress can lead to
apoptosis.11 ER stress due to misfolded proteins can cause cell
death and dysfunction, which can pave the road for other
diseases such as diabetes, ischemia, neurodegeneration and
reperfusion injury by disturbing cell homeostasis.64 Here, we
suggest that PCNXL2 is involved in regulation of endoplasmic
reticulum architecture by facilitating regulatory machinery. As
is evident from this study, PCNXL2 constitutes a J protein family
domain (DNA_J) that is a member of the hsp40 molecular
chaperone family; this may correspond to stress by degradation
of misfolded proteins. Therefore, it can be concluded that
aberrant expression of PCNXL2 may lead to accumulation of
misfolded proteins, and dysregulation of UPR can aﬀect not
only the stress responses of the ER but also the regulation of the
architecture of ER.65
This work has shown that interference with the gene regu-
latory network can challenge the expression of tumor
suppressor genes; especially, PCNXL2 can up-regulate the NotchRSC Adv., 2018, 8, 21414–21430 | 21427
Fig. 9 Illustration of the methodology ﬂow sheet. Functional and structural characterization of PCNXL2 was achieved by performing 10 steps.
The sequence was retrieved from NCBI. Physiochemical properties and conserved domains were predicted using the Pfam and Protpram tools.
SOUSI server was used to identify the location and nature of the protein. The interactions of PCNXL2 with other proteins were investigated by
string analysis. CYSPRED, CYSCON and DIANAwere used to estimate disulphide bonding patterns within the protein. The structurewas predicted
using Raptor X and ITASSER. miRTarBase was used to identifymiRNAs targeting PCNXL2 in diﬀerent cancers. COACHwas used to identify protein
ligand binding sites. Finally, the pathway was designed by reviewing literature studies and KEGG pathways.
21428 | RSC Adv., 2018, 8, 21414–21430 This journal is © The Royal Society of Chemistry 2018
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View Article Onlinesignaling pathway, which determines cell fate by avoiding the
deregulation of N signaling. The current results challenge the
role of the pecanex protein as a cancer biomarker for patient
prognosis and therapeutic intervention by resolving the tumor
suppressor function of Notch in many cancers, such as prostate
and colorectal cancer, and other biological processes. There-
fore, in future experiments, it will be important to determine
the link between human hereditary diseases and ER structural
dysregulation and the cancer biomarker role of PCNXL2 in the
absence of pcx function.Conclusion
This study concludes that PCNXL2 is a tumor suppressor
protein that plays a valuable role in regulating the Notch
signaling pathway in humans. We also speculate that the
PCNXL2 DNA_J domain is involved in the regulation of ER
architecture by coping with ER stress. PCNXL2 encodes a multi-
pass transmembrane protein of 1054 amino acids in humans
comprising the pcx domain and domain A. Structural and
functional characterization of the domains demonstrated that
the pcx protein may regulate Notch signaling by providing
suitable membrane potential to g secretase through liberation
of the Notch intracellular domain, NICD, inside the cell. The pcx
protein also facilitates transportation of NICD from the cyto-
plasm to the nucleus to express tumor suppressor proteins in
fate-determining cells. Several cancers, including prostate and
colorectal, develop in humans due to disruption of Notch
signaling; however, PCNXL2 is found to be directly linked with
activation of Notch signaling, designating its role as a cancer
biomarker in cancerous cells. To our knowledge, this is the rst
report of the molecular function of PCNXL2 based upon its 3-
dimensional structure; it opens up new perspectives for analysis
of the cancer biomarker role of PCNXL2. Future research should
be conducted to elucidate the association of ER biology with
cellular environment changes.Conﬂicts of interest
There are no conicts to declare.References
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